RAPIVAB (bioCSL Inc.)
Welcome to the PulseAid listing for the RAPIVAB drug offered from bioCSL Inc.. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | bioCSL Inc. |
| NON-PROPRIETARY NAME: | Peramivir |
| SUBSTANCE NAME: | PERAMIVIR |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | |
| ROUTE: | INTRAVENOUS |
| DOSAGE FORM: | SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2014-12-20 |
| END MARKETING DATE: | 0000-00-00 |
RAPIVAB HUMAN PRESCRIPTION DRUG Details:
| Item Description | RAPIVAB from bioCSL Inc. |
| LABELER NAME: | bioCSL Inc. |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 600(mg/60mL) |
| START MARKETING DATE: | 2014-12-20 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 61364-181_81cacc91-52f2-43ce-a883-41352b1bbed3 |
| PRODUCT NDC: | 61364-181 |
| APPLICATION NUMBER: | NDA206426 |
Other PERAMIVIR Pharmaceutical Manufacturers / Labelers:
